Effect of topical ophthalmic application of cidofovir on experimentally induced primary ocular feline herpesvirus-1 infection in cats

American Journal of Veterinary Research

Volumn 69, Issue 2, 2008, Pages 289-293

  Fontenelle, Jennifer P ^a,b   Powell, Cynthia C ^a   Veir, Julia K ^a   Radecki, Steven V ^a   Lappin, Michael R ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAT DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; HERPES SIMPLEX KERATITIS; HERPES SIMPLEX VIRUS 1; MALE; NONHUMAN; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SCORING SYSTEM; VIRUS SHEDDING;

ADMINISTRATION, TOPICAL; ANIMALS; ANTIVIRAL AGENTS; CAT DISEASES; CATS; CONJUNCTIVITIS, VIRAL; CYTOSINE; DRUG ADMINISTRATION SCHEDULE; HERPESVIRIDAE; HERPESVIRIDAE INFECTIONS; MALE; PHOSPHONIC ACIDS;

ANIMALIA; FELID HERPESVIRUS 1;

EID: 39549089079     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.69.2.289     Document Type: Article

References (27)

1. Nasisse MP, Guy JS, Davidson MG, et al. In vitro susceptibility of feline herpesvirus-1 to vidarabine, idoxuridine, trifluridine, acyclovir, or bromovinyldeoxyuridine. Am J Vet Res 1989; 50:158-160.
2. Nasisse MP, Davis BJ, Guy JS, et al. Isolation of feline herpesvirus 1 from the trigeminal ganglia of acutely and chronically infected cats. J Vet Intern Med 1992;6:102-103.
3. Gaskell RM, Dennis PE, Goddard LE. Isolation of feline herpesvirus 1 from the trigeminal ganglia of latently infected cats. J Gen Virol 1985;66:391-394.
4. Ohmura Y, Ono E, Matsuura T, et al. Detection of feline herpesvirus 1 transcripts in trigeminal ganglia of latently infected cats. Arch Virol 1993;129:341-347.
5. Gaskell RM, Povey RC. Experimental induction of feline vital rhinotracheitis re-excretion in FVR recovered cats. Vet Rec 1977;100:128-133.
6. Stiles J. Feline herpesvirus. Vet Clin North Am Small Anim Pract 2000;30:1001-1014.
7. Burgesser KM, Hotaling S, Schiebel A, et al. Comparison of PCR, virus isolation, and indirect fluorescent antibody staining in the detection of naturally occurring feline herpesvirus infections. J Vet Diagn Invest 1999;11:122-126.
8. Lappin MR, Andrews J, Simpson D, et al. Use of serologic tests to predict resistance to feline herpesvirus 1, feline calicivirus, and feline parvovirus infection in cats. J Am Vet Med Assoc 2002;220:38-42.
9. Maggs DJ, Nasisse MP, Kass PH. Efficacy of oral supplementation with L-lysine in cats latently infected with feline herpesvirus. Am J Vet Res 2003;64:37-42.
10. Stiles J, Townsend WM, Rogers QR, et al. Effect of oral administration of L-lysine on conjunctivitis caused by feline herpesvirus in cats. Am J Vet Res 2002;63:99-103.
11. Kaufman HE, Varnell ED, Thompson HW. Trifluridine, cidofovir, and penciclovir in the treatment of experimental herpetic keratitis. Arch Ophthalmol 1998;116:777-780.
12. Kaufman HE, Varnell ED, Thompson HW. Cidofovir and experimental herpetic stromal disease. Arch Ophthalmol 1999;117:925-928.
13. Hillenkamp J, Reinhard T, Ross RS, et al. The effects of cidofovir 1% with and without cyclosporin a 1% as a topical treatment of acute adenoviral keratoconjunctivitis: a controlled clinical pilot study. Ophthalmology 2002;109:845-850.
14. Hillenkamp J, Reinhard T, Ross RS, et al. Topical treatment of acute adenoviral keratoconjunctivitis with 0.2% cidofovir and 1% cyclosporine: a controlled clinical pilot study Arch Ophthalmol 2001;119:1487-1491.
15. Maggs DJ, Chang E, Nasisse MP, et al. Persistence of herpes simplex virus type 1 DNA in chronic conjunctival and eyelid lesions of mice. J Virol 1998;72:9166-9172.
16. Vögtlin A, Fraefel C, Albini S, et al. Quantification of feline herpesvirus 1 DNA in ocular fluid samples of clinically diseased cats by real-time PCR. J Clin Microbiol 2002;40:519-523.
17. Leutenegger CM, Klein D, Hofmann-Lehmann R, et al. Rapid feline immunodeficiency virus provirus quantitation by polymerase chain reaction using the TaqMan fluorogenic real-time detection system. J Virol Methods 1999;78:105-116.
18. De Clercq E. Therapeutic potential of cidofovir (HPMPC, Vistide) for the treatment of DNA virus (ie herpes-, papova-, pox-, and adenovirus) infections. Verh K Acad Geneeskd Belg 1996;58:19-47.
19. Maggs DJ, Clarke HE. In vitro efficacy of ganciclovir, cidofovir, penciclovir, foscarnet, idoxuridine, and acyclovir against feline herpesvirus type-1. Am J Vet Res 2004;65:399-403.
20. De Clercq E. Acyclic nucleoside phosphonates in chemotherapy of DNA virus and retrovirus infections. Intervirology 1997;40:295-303.
21. Romanowski EG, Bartels SP, Gordon YJ. Comparative antiviral efficacies of cidofovir, trifluridine, and acyclovir in the HSV-1 rabbit keratitis model. Invest Ophthalmol Vis Sci 1999;40:378-384.
22. Owens JG, Nasisse MP, Tadepalli SM, et al. Pharmacokinetics of acyclovir in the cat. J Vet Pharmacol Ther 1996;19:488-490.
23. Nasisse MP, Dorman DC, Jamison KC, et al. Effects of valacyclovir in cats infected with feline herpesvirus 1. Am J Vet Res 1997;58:1141-1144.
24. Gordon YJ, Romanowski EG, Aroullo-Cruz T. Topical HPMPC inhibits adenovirus type 5 in the New Zealand rabbit ocular replication model. Invest Ophthalmol Vis Sci 1994;35:4135-4143.
25. Taskintuna I, Banker AS, Rao NA, et al. An animal model for cidofovir (HPMPC) toxicity: intraocular pressure and histopathologic effects. Exp Eye Res 1997;64:795-806.
26. Pavan-Langston DL, Dunkel EC. Antiviral drugs. In: Handbook of ocular drug therapy and ocular side effects of systemic drugs. Boston: Little Brown, 1991;159-163.
27. Sherman MD, Feldman KA, Farahmand SM, et al. Treatment of conjunctival squamous cell carcinoma with topical cidofovir. Am J Ophthalmol 2002;134:432-433.